These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31335987)

  • 1. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
    Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
    Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN Expression, Not Mutation Status in
    Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
    Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
    Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
    Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
    Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
    Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
    Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
    PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TSC1/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study.
    Jacob LA; Shafi G
    Indian J Cancer; 2019; 56(3):274-275. PubMed ID: 31389395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
    Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
    Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
    Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
    Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
    Tjota MY; Wanjari P; Segal J; Antic T
    Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
    Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
    BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biallelic
    Maroto P; Anguera G; Roldan-Romero JM; Apellániz-Ruiz M; Algaba F; Boonman J; Nellist M; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C
    J Natl Compr Canc Netw; 2018 Apr; 16(4):352-358. PubMed ID: 29632054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia.
    Potter SL; Venkatramani R; Wenderfer S; Graham BH; Vasudevan SA; Sher A; Wu H; Wheeler DA; Yang Y; Eng CM; Gibbs RA; Roy A; Plon SE; Parsons DW
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27748010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
    BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
    Alsidawi S; Kasi PM
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
    Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
    Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
    Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
    Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
    Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.